Display options
Cite
Huang PC, Kuo WW, Shen CY, et al. Anthocyanin Attenuates Doxorubicin-Induced Cardiomyotoxicity via Estrogen Receptor-α/β and Stabilizes HSF1 to Inhibit the IGF-IIR Apoptotic Pathway. Int J Mol Sci. 2016;17(9)doi: 10.3390/ijms17091588.
Huang, P. C., Kuo, W. W., Shen, C. Y., Chen, Y. F., Lin, Y. M., Ho, T. J., Padma, V. V., Lo, J. F., Huang, C. Y., & Huang, C. Y. (2016). Anthocyanin Attenuates Doxorubicin-Induced Cardiomyotoxicity via Estrogen Receptor-α/β and Stabilizes HSF1 to Inhibit the IGF-IIR Apoptotic Pathway. International journal of molecular sciences, 17(9), . https://doi.org/10.3390/ijms17091588
Huang, Pei-Chen, et al. "Anthocyanin Attenuates Doxorubicin-Induced Cardiomyotoxicity via Estrogen Receptor-α/β and Stabilizes HSF1 to Inhibit the IGF-IIR Apoptotic Pathway." International journal of molecular sciences vol. 17,9 (2016). doi: https://doi.org/10.3390/ijms17091588
Huang PC, Kuo WW, Shen CY, Chen YF, Lin YM, Ho TJ, Padma VV, Lo JF, Huang CY, Huang CY. Anthocyanin Attenuates Doxorubicin-Induced Cardiomyotoxicity via Estrogen Receptor-α/β and Stabilizes HSF1 to Inhibit the IGF-IIR Apoptotic Pathway. Int J Mol Sci. 2016 Sep 21;17(9). doi: 10.3390/ijms17091588. PMID: 27657062; PMCID: PMC5037853.
Copy Download .nbib Format: NLM
Share it on

Int J Mol Sci. 2016 Sep 21;17(9). doi: 10.3390/ijms17091588.

Anthocyanin Attenuates Doxorubicin-Induced Cardiomyotoxicity via Estrogen Receptor-α/β and Stabilizes HSF1 to Inhibit the IGF-IIR Apoptotic Pathway.

International journal of molecular sciences

Pei-Chen Huang, Wei-Wen Kuo, Chia-Yao Shen, Yu-Feng Chen, Yueh-Min Lin, Tsung-Jung Ho, V Vijaya Padma, Jeng-Fan Lo, Chih-Yang Huang, Chih-Yang Huang

Affiliations

  1. Graduate Institute of Clinical Medical Science, China Medical University, Taichung 40402, Taiwan. [email protected].
  2. Department of Obstetrics and Gynecology, China Medical University Hospital, China Medical University, Taichung 40402, Taiwan. [email protected].
  3. Department of Biological Science and Technology, China Medical University, Taichung 40402, Taiwan. [email protected].
  4. Department of Nursing, Mei Ho University, Pingguang Road, Pingtung 91202, Taiwan. [email protected].
  5. Section of Cardiology, Yuan Rung Hospital, Yuanlin 51045, Taiwan. [email protected].
  6. Department of Pathology, Changhua Christian Hospital, Changhua 500, Taiwan. [email protected].
  7. Jen-Teh Junior College of Medicine, Nursing and Management, Miaoli 35664, Taiwan. [email protected].
  8. Chinese Medicine Department, China Medical University Beigang Hospital, Taichung 40402, Taiwan. [email protected].
  9. Department of Biotechnology, Bharathiar University, Coimbatore 641046, India. [email protected].
  10. Institute of Oral Biology, National Yang-Ming University, Taipei 11221, Taiwan. [email protected].
  11. Translation Research Core, China Medical University Hospital, China Medical University, Taichung 40402, Taiwan. [email protected].
  12. Graduate Institute of Basic Medical Science, China Medical University, Taichung 40402, Taiwan. [email protected].
  13. Graduate Institute of Chinese Medical Science, China Medical University, Hsueh-Shih Road, Taichung 40402, Taiwan. [email protected].
  14. Department of Health and Nutrition Biotechnology, Asia University, Taichung 40402, Taiwan. [email protected].

PMID: 27657062 PMCID: PMC5037853 DOI: 10.3390/ijms17091588

Abstract

Doxorubicin (Dox) is extensively used for chemotherapy in different types of cancer, but its use is limited to because of its cardiotoxicity. Our previous studies found that doxorubicin-induced insulin-like growth factor II receptor (IGF-IIR) accumulation causes cardiomyocytes apoptosis via down-regulation of HSF1 pathway. In these studies, we demonstrated a new mechanism through which anthocyanin protects cardiomyoblast cells against doxorubicin-induced injury. We found that anthocyanin decreased IGF-IIR expression via estrogen receptors and stabilized heat shock factor 1 (HSF1) to inhibit caspase 3 activation and apoptosis of cardiomyocytes. Therefore, the phytoestrogen from plants has been considered as another potential treatment for heart failure. It has been reported that the natural compound anthocyanin (ACN) has the ability to reduce the risk of cardiovascular disease (CVD). Here, we demonstrated that anthocyanin acts as a cardioprotective drug against doxorubicin-induced heart failure by attenuating cardiac apoptosis via estrogen receptors to stabilize HSF1 expression and down-regulated IGF-IIR-induced cardiomyocyte apoptosis.

Keywords: IGF-IIR signaling; anthocyanin; apoptosis; cardiomyocyte; doxorubicin; estrogen receptors

Conflict of interest statement

The authors declare no conflict of interest.

References

  1. Cancer Res. 1983 Feb;43(2):460-72 - PubMed
  2. Genes Nutr. 2012 Apr;7(2):295-306 - PubMed
  3. PLoS One. 2010 Jan 01;5(1):e8554 - PubMed
  4. Biomed Res Int. 2013;2013:313905 - PubMed
  5. EMBO J. 2003 Oct 15;22(20):5446-58 - PubMed
  6. Curr Med Chem. 2009;16(25):3267-85 - PubMed
  7. J Mol Endocrinol. 2008 Aug;41(2):65-74 - PubMed
  8. J Mol Cell Cardiol. 2011 Oct;51(4):614-8 - PubMed
  9. BMC Complement Altern Med. 2014 Sep 25;14:358 - PubMed
  10. Front Neuroendocrinol. 2010 Oct;31(4):400-19 - PubMed
  11. Biochem J. 2002 Nov 1;367(Pt 3):729-40 - PubMed
  12. Expert Opin Drug Saf. 2006 Nov;5(6):791-809 - PubMed
  13. Biomed Pharmacother. 2013 Mar 1;3(1):34-42 - PubMed
  14. Am J Cardiol. 2002 Jun 20;89(12A):12E-17E; discussion 17E-18E - PubMed
  15. J Nutr. 2011 Apr 1;141(4):618-25 - PubMed
  16. N Engl J Med. 1999 Jun 10;340(23):1801-11 - PubMed
  17. Cell Death Differ. 2014 Aug;21(8):1262-74 - PubMed
  18. J Physiol. 2015 Apr 15;593(8):1887-99 - PubMed
  19. Hypertension. 2004 Dec;44(6):789-95 - PubMed
  20. Circ Res. 2009 Jan 30;104(2):265-75, 11p following 275 - PubMed
  21. Cardiovasc Res. 2012 Aug 1;95(3):290-9 - PubMed
  22. J Cell Mol Med. 2009 Sep;13(9B):3655-67 - PubMed
  23. Life Sci. 2005 Dec 12;78(4):347-56 - PubMed
  24. J Agric Food Chem. 2002 Aug 28;50(18):5034-7 - PubMed
  25. Food Chem Toxicol. 2007 Oct;45(10):1873-81 - PubMed
  26. Int J Endocrinol. 2014;2014:847827 - PubMed
  27. Food Chem. 2013 Jun 1;138(2-3):1856-67 - PubMed
  28. J Biochem Mol Toxicol. 2004;18(2):69-77 - PubMed
  29. J Am Coll Cardiol. 2007 Jun 26;49(25):2457-64 - PubMed
  30. FEBS Lett. 2009 Feb 4;583(3):531-41 - PubMed
  31. Bioorg Med Chem Lett. 2016 Jan 1;26(1):181-5 - PubMed
  32. Am J Physiol Endocrinol Metab. 2006 Aug;291(2):E306-14 - PubMed
  33. Hypertension. 2004 Aug;44(2):217-22 - PubMed
  34. Biochem Pharmacol. 2012 Jun 15;83(12):1602-12 - PubMed
  35. Mol Cell Biol. 2008 Jun;28(12 ):4018-25 - PubMed
  36. Cancer Chemother Pharmacol. 2012 Dec;70(6):833-41 - PubMed
  37. J Biomed Nanotechnol. 2015 Nov;11(11):1975-88 - PubMed
  38. J Endocrinol. 2008 May;197(2):381-90 - PubMed
  39. Cardiovasc Diabetol. 2015 Oct 21;14:143 - PubMed
  40. FASEB J. 1999 Jul;13(10):1137-43 - PubMed
  41. Am J Chin Med. 2015;43(8):1567-91 - PubMed
  42. Am J Physiol Regul Integr Comp Physiol. 2004 Feb;286(2):R233-49 - PubMed
  43. J Pharm Sci. 2007 Aug;96(8):1879-85 - PubMed
  44. Cardiovasc Toxicol. 2010 Dec;10(4):283-94 - PubMed
  45. Trends Endocrinol Metab. 2014 Mar;25(3):138-45 - PubMed
  46. J Cell Sci Ther. 2014 Jan 30;5(1):153 - PubMed
  47. Food Chem Toxicol. 2013 Jun;56:28-39 - PubMed
  48. Arch Biochem Biophys. 2008 Aug 15;476(2):102-6 - PubMed
  49. J Cell Biochem. 2015 Jun;116(6):1113-20 - PubMed
  50. J Clin Invest. 2014 Feb;124(2):617-30 - PubMed
  51. J Pharm Pharmacol. 2013 Feb;65(2):157-70 - PubMed
  52. Am J Clin Nutr. 2004 Sep;80(3):621-5 - PubMed
  53. Endocrinology. 2009 Jun;150(6):2723-31 - PubMed
  54. Clin Pharmacol Ther. 2014 Jan;95(1):45-52 - PubMed
  55. Curr Med Chem Anticancer Agents. 2001 Aug;1(2):113-30 - PubMed
  56. Mol Cells. 2014 Nov;37(11):812-8 - PubMed
  57. Basic Res Cardiol. 2012 Jul;107(4):273 - PubMed
  58. Pharmacol Rep. 2009 Jan-Feb;61(1):154-71 - PubMed
  59. J Mol Endocrinol. 2009 Dec;43(6):221-30 - PubMed
  60. Free Radic Biol Med. 2007 Feb 15;42(4):466-73 - PubMed
  61. Cancer Chemother Pharmacol. 1979;2(1):77-9 - PubMed
  62. Free Radic Biol Med. 2009 Jun 15;46(12):1589-97 - PubMed
  63. Biochem J. 2005 Jul 15;389(Pt 2):527-39 - PubMed
  64. Oxid Med Cell Longev. 2014;2014:713894 - PubMed
  65. Circ Res. 2010 Jun 11;106(11):1692-702 - PubMed
  66. Genet Mol Res. 2014 Jan 21;13(1):323-35 - PubMed
  67. Cell Biol Toxicol. 2007 Jan;23(1):15-25 - PubMed
  68. Mol Nutr Food Res. 2015 Dec;59(12 ):2419-31 - PubMed
  69. Am J Physiol Renal Physiol. 2001 Mar;280(3):F365-88 - PubMed
  70. Circulation. 2001 Jan 16;103(2):258-62 - PubMed

Publication Types